睿知中国医院研究地图
候选清单

正在招募冠心病不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

ClinicalTrials.gov 上登记的一项冠心病开放试验,由郑州大学第一附属医院牵头,本站收录的另外 4 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 5

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  2. 研究中心河南中医药大学第一附属医院First Affiliated Hospital of Henan University of Chinese Medicine郑州医院页面
  3. 研究中心河南科技大学第一附属医院First Affiliated Hospital of Henan University of Science and Technology洛阳医院页面
  4. 研究中心中国医学科学院阜外心血管病医院Fuwai Hospital北京医院页面
  5. 研究中心Kaifeng Central Hospital新乡医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07463664,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 2

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(2 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Female patients of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use an effective method of contraception throughout the study period.

    入选标准第 10 条

    Female patient is pregnant or breastfeeding.

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);既往治疗;日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07463664,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patient voluntarily participates in the study and has provided written informed consent.
  2. Presence of clinical indication for Percutaneous Coronary Intervention (PCI) of the Chronic Total Occlusion (CTO) (e.g., symptoms of angina pectoris or evidence of myocardial ischemia).
  3. Target lesion is located in a de novo coronary artery.
  4. Angiographically confirmed CTO (TIMI grade 0 flow), with evidence supporting an occlusion duration of ≥ 3 months.
  5. Successful guidewire crossing of the target CTO lesion has been achieved during the index procedure.
  6. After adequate vessel preparation: Distal TIMI grade 3 flow has been restored; Target lesion residual diameter stenosis is < 50% (e.g., by visual estimate or QCA as per protocol); Absence of flow-limiting dissection or other complications requiring immediate stent implantation.
  7. Target vessel Reference Vessel Diameter (RVD) is between 2.25 mm and 4.0 mm (inclusive, assessed by visual estimate or QCA/IVUS as per protocol).
  8. In the judgment of the interventional operator, the lesion is deemed suitable for treatment with both a Drug-Coated Balloon (DCB)-based strategy and a Drug-Eluting Stent (DES)-only strategy.
  9. Patient is able and willing to comply with the study protocol requirements, including the specified follow-up schedule.
  10. Female patients of childbearing potential must have a negative pregnancy test prior to enrollment and agree to use an effective method of contraception throughout the study period.

排除标准:Exclusion Criteria:

  1. Target CTO lesion is the culprit vessel responsible for the presenting Acute Myocardial Infarction (AMI).
  2. Patient is in cardiogenic shock.
  3. Presence of severe heart failure (New York Heart Association [NYHA] Class IV) or Left Ventricular Ejection Fraction (LVEF) < 30%.
  4. History of stroke or Transient Ischemic Attack (TIA) within the previous 3 months.
  5. Known high risk of bleeding or contraindication to Dual Antiplatelet Therapy (DAPT).
  6. Presence of severe hepatic impairment and/or severe renal impairment (e.g., estimated Glomerular Filtration Rate [eGFR] < 30 ml/min/1.73m² or requirement for chronic dialysis).
  7. Known hypersensitivity or contraindication to required study medications (e.g., antiplatelet agents, contrast media), DCB/DES drug coatings, or device materials (e.g., stent alloys, polymers).
  8. Target lesion located in an unprotected left main coronary artery, a saphenous vein graft, or an arterial graft.
  9. Presence of severe lesion calcification that prevents adequate vessel expansion despite attempted lesion preparation techniques (e.g., rotational atherectomy, intravascular lithotripsy).
  10. Target lesion is a CTO within a previously stented segment (In-Stent Restenosis [ISR] or In-Stent Thrombosis [IST]).
  11. Failed attempt at CTO recanalization during the index procedure (i.e., failure to cross the lesion with a guidewire or failure to restore TIMI grade 3 flow).
  12. Occurrence of a complication after vessel preparation that necessitates immediate stent implantation (e.g., flow-limiting dissection, perforation requiring a covered stent).
  13. Concurrent enrollment in another interventional clinical trial that may interfere with the study endpoints or assessments.
  14. Female patient is pregnant or breastfeeding.
  15. Patient judged by the investigator to be unsuitable for the study for any reason, including anticipated poor compliance with the protocol.

引自 ClinicalTrials.gov, NCT07463664, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07463664,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07463664